Human Metabolome Technologies (HMT) starts sales of biomarkers

HMT is working on the development of biomarkers for depression, and since November 2016 started selling reagents for research purposes through its subsidiary, HMT Biomedical. Since February 2017, biomarkers are included in the portfolio.

Nikkei Biotech news release, February 21, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny